Brown Advisory Inc Zentalis Pharmaceuticals, Inc. Transaction History

Brown Advisory Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$41.58 - $80.89 $124,740 - $242,670	-3,000 Closed	0 $0
Q4 2021 Jan 27, 2022	SELL	$66.92 - $84.79 $133,840 - $169,580	-2,000 Reduced 40.0%	3,000 $252,000
Q3 2021 Nov 12, 2021	SELL	$46.83 - $73.5 $93,660 - $147,000	-2,000 Reduced 28.57%	5,000 $333,000
Q2 2021 Jul 29, 2021	SELL	$37.41 - $62.25 $18,705 - $31,125	-500 Reduced 6.67%	7,000 $372,000
Q1 2021 May 14, 2021	SELL	$35.69 - $52.72 $16,346 - $24,145	-458 Reduced 5.76%	7,500 $325,000
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $252,348 - $461,325	7,958 New	7,958 $413,000

141

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $184M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.